Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda agrees to acquire Shire for £45.3bn
As per the terms of the deal, the Japanese pharma company will pay $30.33 in cash for each Shire share along with either 0.839 new Takeda shares or
As per the terms of the deal, the Japanese pharma company will pay $30.33 in cash for each Shire share along with either 0.839 new Takeda shares or
The deal gives Luye the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand,
The US Food and Drug Administration (FDA), which accepted the company’s supplemental Biologics License Application (sBLA), gave the designation for the combination to be used as first-line treatment
The approval is for patients in whom the tumor cannot be removed by surgery or has spread to other parts of the body, and has the abnormal gene,
Horizon secured an unsolicited and highly conditional proposal from Abcam. Abcam has offered £1.81 per Horizon share, which represents a premium of only 25.7% to its share on 1
The deal now includes shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine. Merck and Moderna will now jointly advance mRNA-5671 in human studies, and
Novartis firm Sandoz received a complete response letter (CRL) regarding the BLA for biosimilar rituximab and is planning to conduct further discussions with FDA to bring the medicine to
Janssen Biotech is one of the Janssen Pharmaceutical Companies owned by Johnson & Johnson. BeneVir is a portfolio company within HC2’s Pansend Life Sciences subsidiary. BeneVir is currently
The new indication approved by the US Food and Drug Administration (FDA) covers diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL. The immunocellular therapy has
The ORR, which was the primary objective of the STORM trial, included two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) across patients with